A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs KHK 6640 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 31 May 2017 Status changed from active, no longer recruiting to completed.
- 07 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017.
- 07 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Apr 2017.